CFTR and cystic fibrosis: Should these observations be confirmed in future human studies, 3-IAld, similarly to CFTR modulators [46], may be endowed with the ability to modify the mucosal milieu to favor a healthier microbiota, which could lead to improvements in pulmonary and extra-pulmonary CF morbidity.